Yelin Lapidot Holdings Management Ltd. Sells 65,590 Shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB)

Yelin Lapidot Holdings Management Ltd. reduced its stake in shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) by 8.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 744,127 shares of the company’s stock after selling 65,590 shares during the quarter. Yelin Lapidot Holdings Management Ltd. owned 0.05% of Chemomab Therapeutics worth $1,347,000 at the end of the most recent reporting period.

Separately, Sphera Funds Management LTD. bought a new stake in Chemomab Therapeutics during the third quarter worth about $1,907,000. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Stock Down 0.6 %

Chemomab Therapeutics stock opened at $1.62 on Friday. Chemomab Therapeutics Ltd. has a twelve month low of $0.58 and a twelve month high of $2.55. The stock’s 50 day moving average is $1.97 and its 200 day moving average is $1.73. The company has a market capitalization of $23.26 million, a P/E ratio of -1.62 and a beta of 0.66.

Wall Street Analysts Forecast Growth

CMMB has been the topic of several recent research reports. Oppenheimer reiterated an “outperform” rating and set a $11.00 price objective (down from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th. Maxim Group boosted their target price on Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, February 20th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).